Please select the option that best describes you:
What mutational testing is considered the standard of care for NSCLC?
Should mutations other then EGFR and ALK be routinely tested for? Should next generation sequencing be routinely done?
Answer from: Medical Oncologist at Academic Institution
The easy answer to this question is that the only molecular alterations for which we have matched FDA-approved drugs for those specific indications are EGFR and ALK, so the standard of care would be to test only for EGFR and ALK. However, over the past 2-3 years, we came to appreciate that several o...
Sign in or Register to read more